(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 May 2006 (18.05.2006)

PCT

(10) International Publication Number
WO 2006/052018 A1

(51) International Patent Classification:
A61K 31/4704 (2006.01) *A61K 47/34* (2006.01)
A61K 9/08 (2006.01) *A61K 47/38* (2006.01)
A61K 9/10 (2006.01) *A61P 27/02* (2006.01)
A61K 47/32 (2006.01)

(21) International Application Number:
PCT/JP2005/021178

(22) International Filing Date:
11 November 2005 (11.11.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2004-330140 15 November 2004 (15.11.2004) JP

(71) Applicant *(for all designated States except US)*: **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 9, Kandatsukasa-cho 2-chome, Chiyoda-ku, Tokyo, 1018535 (JP).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MATSUDA, Takakuni** [JP/JP]; Corpo-Faburesu B-201, 145, Tainohama-Aza-Hara, Kitajima-cho, Itano-gun, Tokushima, 7710204 (JP). **HIRAOKA, Shogo** [JP/JP]; Apricot 103, 4-1, Tainohama-Aza-Onishi, Kitajima-cho, Itano-gun, Tokushima, 7710204 (JP). **TOMOHIRA, Yuso** [JP/JP]; 3-1-31, Tsudahon-cho, Tokushima-shi, Tokushima, 7708003 (JP). **ISHIKAWA, Shinichi** [JP/JP]; 10, Aza-Ebisu, Niimi-cho, Komatsushima-shi, Tokushima, 7730011 (JP).

(74) Agents: **KAWAMIYA, Osamu** et al.; AOYAMA & PARTNERS, IMP Building, 3-7, Shiromi 1-chome, Chuo-ku, Osaka-shi, Osaka 5400001 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** AQUEOUS OPHTHALMIC SUSPENSION OF CRYSTALLINE REBAMIPIDE

(57) **Abstract:** The invention provides an ophthalmic product containing rebamipide, which has a transparency enough to be agreeable feeling on using it and has neutral to weakly acidic pH not to injury of the keratoconjunctiva of a patient suffering from dry eye. An aqueous suspension of crystalline rebamipide which has an improved transparency is provided by adding an aqueous solution of rebamipide dissolved by a base such as sodium hydroxide or an aqueous solution of a salt of rebamipide to an aqueous acidic solution such as hydrochloric acid containing at least one of the compounds selected from water-soluble polymers and surfactants, and mixing them.

WO 2006/052018 A1